TY - JOUR
T1 - Evidence that G-quadruplexes form in pathogenic fungi and represent promising antifungal targets
AU - Middleton, Georgie
AU - Mahamud, Fuad O.
AU - Storer, Isabelle S. R.
AU - Williams-Gunn, Abigail
AU - Wostear, Finn
AU - Abdolrasouli, Alireza
AU - Barclay, Elaine
AU - Bradford, Alice
AU - Steward, Oliver
AU - Schelenz, Silke
AU - McColl, James
AU - Lézé, Bertrand
AU - van Rhijn, Norman
AU - da Silva Dantas, Alessandra
AU - Furukawa, Takanori
AU - Warren, Derek
AU - Waller, Zoë A. E.
AU - Bidula, Stefan
N1 - Data availability: The source data of this paper are collected in the following database record https://doi.org/10.5281/zenodo.17192248. The source data of this paper are collected in the following database record: biostudies:S-SCDT-10_1038-S44321-025-00340-1.
Funding: This work was supported by the Academy of Medical Sciences [SBF008\1046 to SB] and [SBF0010\1140 to TF], British Mycological Society to TF, Biotechnology and Biological Sciences Research Council [BB/Y005058/1 to SB; BB/W001616/1 to ZAEW], Wellcome Trust [226408/Z/22/Z to NvR], Royal Society Research Grant [RG\R2\232363] and the NIHR Newcastle Biomedical Research Centre (BRC) to AdSD, and Thomas Marns Scholarship to FOM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
PY - 2025/12/8
Y1 - 2025/12/8
N2 - Fungi are estimated to cause the death of almost 4 million people annually, and we urgently need new drug targets to overcome antifungal resistance. We found that four-stranded nucleic acid structures called G-quadruplexes (G4s) could form within the critical priority fungal pathogen Aspergillus fumigatus. Sequences with the potential to form G4s could be found in genes involved in fungal growth, virulence, and drug resistance. This included cyp51A, which encodes the target of azoles. Notably, we observed the formation of both canonical and unusual acid-stabilised G4s in these sequences. We found that PhenDC3 (a G4-stabilising ligand) could refold DNA into antiparallel G4 structures in cyp51A that were associated with decreased transcription. PhenDC3 also had potent fungistatic activity, prevented germination, synergised with the antifungal amphotericin B in vitro and in vivo, and displayed low genotoxicity and cytotoxicity towards human cells. Interestingly, PhenDC3 had greater antifungal activity towards the pan-azole-resistant A. fumigatus TR34/L98H isolate, and another G4-stabiliser, pyridostatin, killed multi-drug-resistant Candida auris. Taken together, G4s represent a promising target for the development of antifungals with novel mechanisms of action.
AB - Fungi are estimated to cause the death of almost 4 million people annually, and we urgently need new drug targets to overcome antifungal resistance. We found that four-stranded nucleic acid structures called G-quadruplexes (G4s) could form within the critical priority fungal pathogen Aspergillus fumigatus. Sequences with the potential to form G4s could be found in genes involved in fungal growth, virulence, and drug resistance. This included cyp51A, which encodes the target of azoles. Notably, we observed the formation of both canonical and unusual acid-stabilised G4s in these sequences. We found that PhenDC3 (a G4-stabilising ligand) could refold DNA into antiparallel G4 structures in cyp51A that were associated with decreased transcription. PhenDC3 also had potent fungistatic activity, prevented germination, synergised with the antifungal amphotericin B in vitro and in vivo, and displayed low genotoxicity and cytotoxicity towards human cells. Interestingly, PhenDC3 had greater antifungal activity towards the pan-azole-resistant A. fumigatus TR34/L98H isolate, and another G4-stabiliser, pyridostatin, killed multi-drug-resistant Candida auris. Taken together, G4s represent a promising target for the development of antifungals with novel mechanisms of action.
KW - Antifungal
KW - Aspergillus
KW - Candida
KW - DNA
KW - G-quadruplex
UR - https://www.scopus.com/pages/publications/105022291900
U2 - 10.1038/s44321-025-00340-1
DO - 10.1038/s44321-025-00340-1
M3 - Article
SN - 1757-4676
VL - 17
SP - 3636
EP - 3656
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
IS - 12
ER -